Arrakis Therapeutics, USA



HBM contact: Dr Chandra P. Leo

Company status: private

Arrakis is pioneering the discovery of small-molecule medicines that directly bind to and modify the biological function of RNA to treat disease. This new class of medicines, RNA-targeted small molecules (rSMs), can unlock the therapeutic potential of deeply researched, valuable targets that are not accessible at the level of their expressed, undruggable protein.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171